Earlier this year, a report from Pharmaceutical Executive detailed the ways in which China is becoming an essential R&D partner for pharma and biotech companies. Also this year, a bipartisan effort launched in Congress to pass a bill that would add biotech the Treasury’s outbound investment screening list. Pharmaceutical Executive: What steps are US regulators taking to promote domestic investment? John Stanford: Last year's National Defense Authorization Act, or NDAA, marked an important moment: biotech is now formally part of the national security conversation. Flipping the switch off risks ceding US leadership and cutting American investors and companies out of the conversation entirely.